New CRO Partner: Redoxis

We are pleased to welcome Redoxis as a new CRO partner. Redoxis is a specialized preclinical contract research organization focused on inflammation and autoimmune disease. This partnership connects Mabtech's ELISpot and FluoroSpot assays, run on the IRIS 2 platform, with Redoxis's disease model and immune profiling expertise, giving joint customers a clear path from early mechanistic work to translational biomarker data.

Together, Mabtech and Redoxis aim to give inflammation and autoimmunity researchers a smoother route from target validation to IND-enabling studies, with cytokine and immune cell readouts built on validated, high-sensitivity methods at every stage.

More on Redoxis and our other CRO partners.